Xenon Gas
Xenon is an inert anaesthetic noble gas reported to stabilise HIF and raise erythropoietin when inhaled. Publicised after claims of use by Russian athletes around 2014, it was added to the WADA Prohibited List as a HIF activating agent. Human performance evidence is weak and detection is difficult.
01 Overview
Xenon inhalation is used medically as an anaesthetic and neuroprotectant. Animal studies suggested xenon (and argon) can stabilise HIF-1alpha and increase erythropoietin, prompting reports that some athletes inhaled xenon-oxygen mixtures to boost red cell production before the 2014 Winter Olympics.\n\nThe human erythropoietic and performance evidence remains thin and disputed, and xenon leaves the body quickly, making detection hard. Nonetheless WADA added xenon and argon to the prohibited list as HIF activating agents in 2014. Risks centre on anaesthetic effects: sedation, loss of consciousness and asphyxiation if inhaled without adequate oxygen.
02 Mechanism
Proposed to stabilise HIF-1alpha (possibly via effects on prolyl hydroxylase / HSP90 pathways), increasing erythropoietin transcription; it is also an NMDA-receptor antagonist producing anaesthesia.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Reported doping use | 30–50 % Xe in O2 | Inhaled | Inhaled mixtures reported anecdotally; efficacy unproven, hazardous |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Claimed rise in erythropoietinAnimal data suggest HIF stabilisation and higher EPO; robust human performance data are lacking. | Uncertain | Preclinical | |
| Rapid clearance / hard to detectXenon is exhaled within minutes, which historically made its use difficult to detect and contributed to its appeal despite prohibition. | Exhaled in minutes | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Sedation / loss of consciousness / asphyxiationAs an anaesthetic gas, xenon can cause sedation and unconsciousness; inhaling without sufficient oxygen risks asphyxiation. | Life-threatening | Depends on mixture | Observational | |
| Unproven benefit / uncharacterised riskPerformance benefit is unproven and any erythropoietic effect could carry the same viscosity/thrombosis risks as other ESAs. | Moderate | Uncharacterised | Preclinical |